Exercise may stop colon cancer from returning — and more
More Coverage: WGN's Medical Watch
Exercise may help prevent colon cancer from returning, according to results from a late-phase trial published Sunday, June 1 in the New England Journal of Medicine.
The study looked at people who followed an exercise program after undergoing surgery and chemotherapy for Stage 3, or high-risk Stage 2 colon cancer.
It found exercise could reduce the risk of the cancer returning, a new cancer diagnosis, or death by 28 percent.
The study participants who reduced their risk had a coach assist them in exercising over the eight-year study period.
The CDC is urging Americans to cancel their upcoming flights if they're not vaccinated against measles.
The agency upgraded its health travel warning after discovering the virus is spreading on US airplanes.
Measles infections have been detected at the country's biggest airports in recent months during a resurgence of the virus linked to low vaccination rates.
It's estimated that around 10 percent of adults may lack immunity, either because they never received a measles vaccine or because their immunity has diminished over time.
Moderna has won FDA approval for a new version of the COVID-19 vaccine.
It will be made available during the upcoming respiratory virus season to people aged 65 and older, and those aged 12 to 64 with at least one underlying health condition that puts them at severe risk.
It's the first big approval by the FDA since it required drug companies to expand their testing.
The new vaccine is called MNEXSPIKE.
Sign up for our Medical Watch newsletter. This daily update includes important information from WGN's Dina Bair and the Med Watch team, including, the latest updates from health organizations, in-depth reporting on advancements in medical technology and treatments, as well as personal features related to people in the medical field. Sign up here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
25 minutes ago
- Business Insider
I'm a dietitian on the Mediterranean diet. Here are 10 things I get at Costco when I'm trying to eat more fiber.
I'm a dietitian who follows the Mediterranean diet and I've been prioritizing consuming more fiber. My favorite things to get at Costco include Kirkland Signature dried plums and frozen berry blends. I buy Kodiak Power Cakes mix and Actual Veggies black-bean burgers in bulk to help hit my goals. "Fibermaxxing" is one of the latest trends on TikTok and, as a dietitian, it's actually one I can get behind. Most Americans aren't coming close to eating enough fiber every day, and the goal of fibermaxxing is to hit or exceed one's suggested daily intake of it. After all, fiber is crucial to a healthy diet. It keeps your digestive system moving and can also help you feel full, support gut health, and play a role in reducing the risk of certain chronic diseases. While upping my fiber game, I also follow the Mediterranean diet — a flexible healthy eating pattern that focuses on maximizing whole grains and fresh produce while limiting processed foods. Costco is one of my go-to spots to stock up on fiber-rich staples in bulk that fit the bill and work with my diet. Here area few of my favorite finds that help me hit my fiber goals without sacrificing flavor or convenience. I add frozen riced cauliflower to my grain dishes and smoothies. A low-carb, high-fiber alternative to rice, frozen riced cauliflower is as versatile as it gets. I buy it in bulk at Costco and add it to my smoothies for a fiber boost that I can't even taste. I also mix it into grain dishes for some extra bulk and antioxidants — it's hard to taste the difference. Good Foods organic avocado mash is delicious on sandwiches. Avocados are fairly high in fiber and I like this ready-to-eat mash from Good Foods that I can buy in bulk at Costco. Each single-serve container has 4 grams of dietary fiber. I love using this as a condiment in my sandwiches instead of mayo. It adds creaminess and heart-healthy fats to my lunch while also boosting my fiber intake. I enjoy SunGold kiwis, skin and all. SunGold kiwis are sweet, juicy, and contain about 2 grams of fiber. I slice them over Greek yogurt or enjoy them on their own for a bright, zesty fiber fix. I will literally bite into them like an apple after washing the skin. (You can consume the skin— it's thin and edible.) Dried plums are one of my go-to snacks. Prunes are famously high in fiber — luckily, they're pretty sweet and versatile. For a snack, I'll eat Kirkland Signature Sunsweet dried prunes right out of the bag or stuff them with nut butter for extra protein. They're also great to blend into smoothies for extra sweetness or to chop to add to salads. I love that frozen berry mixes come with a fairly long shelf life. Frozen fruit can be just as nutritious as fresh and oftentimes, it's much more economical. I especially like the Kirkland Signature triple-berry blend, which contains raspberries, blueberries, and blackberries. This antioxidant-loaded mix is a dietitian's dream. I toss the berries into my breakfast bowls, blend them into smoothies, and just snack on them straight from the bag. With these, I can have a naturally sweet fiber boost without having to worry about eating tons of fresh fruit before it gets moldy and mushy. Actual Veggies black-bean veggie burgers are convenient on weeknights. Compared to traditional beef burgers (which have no fiber), these plant-based patties feel like a fiber goldmine. Each patty contains 6 grams of fiber. I lean on these for nights when I really don't feel like cooking and a burger is calling my name. All I have to do is heat a patty up and enjoy it with a whole-grain bun, veggies, some avocado mash, and a side salad. Catalina Crunch protein cereal can be a high-fiber snack or breakfast. If you're really trying to fibermaxx, a high-fiber cereal can be a great breakfast option. Although it's advertised as a protein cereal, Catalina Crunch also doesn't disappoint in the fiber department. It contains a whopping 9 grams of fiber per serving — much more than what other classic cinnamon-toast cereals provide. And, in my humble opinion, it tastes just as good. I use it as a yogurt topper, mix it with other cereals for breakfast, or eat it on its own as a snack. I sprinkle chia seeds on so many dishes. These tiny seeds pack a big punch when it comes to fiber at about 10 grams per serving. I sprinkle them on yogurt, blend them into smoothies, or make chia pudding for a fiber-rich snack. Chia seeds are also high in omega-3s, another Mediterranean-diet darling that can be great for heart health. Organic mushrooms add fiber and volume to a lot of my beef dishes. I use mushrooms to add a meaty texture, earthy flavor, and a touch of fiber to countless dinner recipes. They work especially well in meat-forward dishes like beef tacos or Bolognese sauce. For those, I replace half of my meat with chopped mushrooms. It's a win-win — I add fiber to my meals and they cost less to make since I use less meat. The mushrooms give me a boost of antioxidants, too. I keep Kodiak Power Cakes flapjack and waffle mix on hand to make breakfasts filled with protein and fiber. My family and I love pancakes and waffles, so I like that this Kodiak Power Cakes mix allows us to enjoy a weekend treat with an impressive amount of protein (15 grams) and fiber (5 grams) per serving. It's even more impressive when you consider that many other pancake mixes contain less than a gram of fiber per serving. I also like to top these pancakes with chia seeds and frozen berries for a super fiber-filled breakfast.
Yahoo
an hour ago
- Yahoo
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine maker reported quarterly sales of $142 million, beating the consensus of $116.34 million. Sales fell 41% from $241 million in the same period in 2024. The decline was primarily driven by lower COVID-19 vaccine sales, which totaled $114 million in the is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine transitions into a seasonal respiratory product. The company reported $114 million in Spikevax sales in the second quarter of 2025, including $88 million in U.S. and $26 million in international sales. Moderna recently announced U.S. Food and Drug Administration (FDA) approval for the supplemental Biologics License Application (sBLA) for Spikevax in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. The company's COVID-19 vaccine (mRNA-1273) was previously available for pediatric populations under Emergency Use Authorization (EUA). Additionally, the company announced it has received final approval from the European Medicines Agency for Spikevax targeting the LP.8.1 variant in individuals six months of age and older. Moderna also announced FDA approval for mNEXSPIKE (mRNA-1283), a next-generation vaccine against COVID-19, for use in all adults aged 65 and older, as well as individuals aged 12-64 years with at least one underlying risk factor. On Wednesday, the European Commission approved the updated formulation of the COVID-19 vaccine Spikevax, targeting the SARS-CoV-2 variant LP.8.1, for individuals six months of age and older. Moderna reported negligible mRESVIA (RSV vaccine) sales in the second quarter of 2025. Moderna's RSV vaccine for adults aged 60 years and older has been approved in approximately 40 countries. Additionally, Moderna recently announced that the FDA has approved mRESVIA (mRNA-1345), expanding the previous indication, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. View more earnings on MRNA Cost of sales for the second quarter of 2025 was $119 million, which included third-party royalties of $6 million, inventory write-downs of $38 million, and unutilized manufacturing capacity and wind-down costs of $52 million. Cost of sales was relatively flat compared to the same period in 2024. The increase in cost of sales as a percentage of net product sales, to 105% from 62% in the second quarter of 2024, was mainly driven by lower net product sales. R&D expenses were $700 million, a 43% decrease year over year. The reduction was primarily driven by lower clinical trial and manufacturing expenses, reflecting reduced production spending, program wind-downs, and the timing of trial activities across the company's respiratory vaccine portfolio. Outlook Moderna has revised its 2025 revenue outlook to $1.5 billion-$2.2 billion compared to $1.5 billion-$2.5 billion, compared to a consensus of $2.09 billion, reflecting a $300 million reduction at the high end of the range. The update is primarily driven by the timing shift of deliveries of contracted revenue for the U.K. into the first quarter of 2026. Moderna expects a revenue split of 40-50% in the third quarter for the second half of the year, with the balance in the fourth quarter of 2025. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of under 5,000 by year-end. Legal Ruling On Friday, Moderna announced that the U.K. Court of Appeal upheld the validity of Moderna's EP'949 patent. European patent EP'949 relates to chemically modified mRNA, one of Moderna's foundational technologies. The decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine, Comirnaty. Pfizer/BioNTech subsequently appealed. With this ruling, the U.K. becomes the first jurisdiction globally to issue a second-instance decision confirming the validity of one of Moderna's core mRNA patents. In Germany, the Regional Court found that Pfizer and BioNTech infringed Moderna's modified mRNA patent and confirmed Moderna's right to seek damages. An appeal is pending. The European Patent Office upheld the validity of EP'949 in opposition proceedings. An appeal is pending. Price Action: Moderna stock is trading 7.92% lower to $27.22 premarket at last check Friday. Read Next:Photo by Lutsenko_Oleksandr via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? MODERNA (MRNA): Free Stock Analysis Report This article Moderna's Key Patent Win Overshadowed By Gloomy Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
CNBC
an hour ago
- CNBC
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
